中国综合临床
中國綜閤臨床
중국종합림상
CLINICAL MEDICINE OF CHINA
2013年
11期
1191-1194
,共4页
王新华%熊重祥%路建饶%刘建萍%洪月琳%王玉华%于阅尽%宋黎涛
王新華%熊重祥%路建饒%劉建萍%洪月琳%王玉華%于閱儘%宋黎濤
왕신화%웅중상%로건요%류건평%홍월림%왕옥화%우열진%송려도
羟苯磺酸钙胶囊%肾炎康复片%糖尿病肾病
羥苯磺痠鈣膠囊%腎炎康複片%糖尿病腎病
간분광산개효낭%신염강복편%당뇨병신병
Calcium dobesilate capsule%Shenyankangfu tablets%Diabetic nephropathy
目的 观察羟苯磺酸钙胶囊联合肾炎康复片治疗糖尿病肾病的临床效果.方法 60例2型糖尿病肾病Ⅳ、Ⅴ期患者被随机分为对照组30例(口服肾炎康复片,5片/次,3次/d)和联合治疗组30例(口服肾炎康复片,5片/次,3次/d；羟苯磺酸钙胶囊,0.5g,3次/d.两组疗程3个月.观察两组患者治疗前后临床症状和体征、尿微量白蛋白排泄率(UAER)、24 h尿蛋白定量以及血液流变学、血肌酐、尿素氮的变化.结果 (1)两组患者临床症状体征均有不同程度改善,治疗组总有效率90.0％ (27/30),而对照组总有效率63.3％ (19/30),治疗组临床疗效明显优于对照组(x2=4.327,P=0.038).(2)两组患者治疗后尿白蛋白排泄率[联合治疗组(175.0±13.5) μg/min、对照组(350.5±79.3)μg/min]和24 h尿蛋白定量[联合治疗组(0.52±0.06) g/24 h、对照组(0.93 ±0.13) g/24 h]均较治疗前[联合治疗组(385.0 ±82.3)μg/min、对照组(386.0±81.2) μμg/min、联合治疗组(0.95±0.13) g/24 h、对照组(0.98 ±0.14) g/24 h]明显下降,但治疗组下降的效果更明显(P＜0.05).(3)治疗组治疗后血肌酐、尿素氮均较治疗前明显下降(P＜0.01),而对照组治疗前后无明显变化.结论 肾炎康复片联合羟苯磺酸钙胶囊是治疗糖尿病肾病一种安全有效的方法.
目的 觀察羥苯磺痠鈣膠囊聯閤腎炎康複片治療糖尿病腎病的臨床效果.方法 60例2型糖尿病腎病Ⅳ、Ⅴ期患者被隨機分為對照組30例(口服腎炎康複片,5片/次,3次/d)和聯閤治療組30例(口服腎炎康複片,5片/次,3次/d；羥苯磺痠鈣膠囊,0.5g,3次/d.兩組療程3箇月.觀察兩組患者治療前後臨床癥狀和體徵、尿微量白蛋白排洩率(UAER)、24 h尿蛋白定量以及血液流變學、血肌酐、尿素氮的變化.結果 (1)兩組患者臨床癥狀體徵均有不同程度改善,治療組總有效率90.0％ (27/30),而對照組總有效率63.3％ (19/30),治療組臨床療效明顯優于對照組(x2=4.327,P=0.038).(2)兩組患者治療後尿白蛋白排洩率[聯閤治療組(175.0±13.5) μg/min、對照組(350.5±79.3)μg/min]和24 h尿蛋白定量[聯閤治療組(0.52±0.06) g/24 h、對照組(0.93 ±0.13) g/24 h]均較治療前[聯閤治療組(385.0 ±82.3)μg/min、對照組(386.0±81.2) μμg/min、聯閤治療組(0.95±0.13) g/24 h、對照組(0.98 ±0.14) g/24 h]明顯下降,但治療組下降的效果更明顯(P＜0.05).(3)治療組治療後血肌酐、尿素氮均較治療前明顯下降(P＜0.01),而對照組治療前後無明顯變化.結論 腎炎康複片聯閤羥苯磺痠鈣膠囊是治療糖尿病腎病一種安全有效的方法.
목적 관찰간분광산개효낭연합신염강복편치료당뇨병신병적림상효과.방법 60례2형당뇨병신병Ⅳ、Ⅴ기환자피수궤분위대조조30례(구복신염강복편,5편/차,3차/d)화연합치료조30례(구복신염강복편,5편/차,3차/d；간분광산개효낭,0.5g,3차/d.량조료정3개월.관찰량조환자치료전후림상증상화체정、뇨미량백단백배설솔(UAER)、24 h뇨단백정량이급혈액류변학、혈기항、뇨소담적변화.결과 (1)량조환자림상증상체정균유불동정도개선,치료조총유효솔90.0％ (27/30),이대조조총유효솔63.3％ (19/30),치료조림상료효명현우우대조조(x2=4.327,P=0.038).(2)량조환자치료후뇨백단백배설솔[연합치료조(175.0±13.5) μg/min、대조조(350.5±79.3)μg/min]화24 h뇨단백정량[연합치료조(0.52±0.06) g/24 h、대조조(0.93 ±0.13) g/24 h]균교치료전[연합치료조(385.0 ±82.3)μg/min、대조조(386.0±81.2) μμg/min、연합치료조(0.95±0.13) g/24 h、대조조(0.98 ±0.14) g/24 h]명현하강,단치료조하강적효과경명현(P＜0.05).(3)치료조치료후혈기항、뇨소담균교치료전명현하강(P＜0.01),이대조조치료전후무명현변화.결론 신염강복편연합간분광산개효낭시치료당뇨병신병일충안전유효적방법.
Objective To investigate the effect of calcium dobesilate capsule combining with Shenyankang tablets in treating diabetic nephropathy.Methods Sixty patients with diabetic nephropathy were randomly divided into two groups.Patients in control group were given Shneyankangfu tablets for 2.4 g,3 times/day,while in treatment group were administrated with Shneyankangfu tablets 2.4 g combined with calcium dobesilate 500 mg,3 times/day,both group for three months treatment course.The levels of blood rheology,serum creatinine,urea nitrogen,24 hours urine protein output,liver function of two groups were measured before and after treatment.Results (1)The clinical signs and symptoms in the two groups were improved at different degree.The total efficiency in the treatment group was significant higher than that of the control group (90％ (27/30) vs.63.3％ (19/30),x2 =4.327,P =0.038).(2) The urinary albumin excretion rate and 24-hour urinary protein excretion after treatment were lower than those before treatment in the two groups.(the treatment group:(175.0 ± 13.5) μg/min vs.(385.0 ± 82.3) μg/min,(0.52 ± 0.06) g/24 h vs.(0.95 ± 0.13) g/24h;the control group:(350.5 ±79.3) μg/min vs.(386.0 ±81.2) μg/min,(0.93 ±0.13) g/24 h vs.(0.98 ± 0.14) g/24 h),and the effect in the treatment group was better than control group (P ＜ 0.05).(3)The serum creatinine,urea nitrogen after treatment were significantly decreased than those before treatment in patient of treatment group (P ＜ 0.01),whereas no significant change was seen before and after treatment in the control group.Conclusion Calcium dobesilate capsule combined with Shenyankangfu tablets was proved an effective and safety method for the treatment of Diabetic nephropathy patients.
